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Drug Discovery Today Volume 25, Number 8 August 2020 REVIEWS
Teaser Advanced age is the major risk factor for multimorbidity. Current clinical practice
treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the
biological processes that drive ageing could prevent both multimorbidity and polypharmacy.
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the drug discovery challenge
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Patients with multimorbidities have shorter life expectancy and their
clinical management is more complex and expensive for healthcare
systems currently focused on treating single diseases. Given that age is the
major risk factor for multimorbidity, the challenge of treating these
patients will only increase in coming years. Here, we review the case for
targeting the core processes that drive the ageing phenotype as a novel
pharmaceutical approach to multimorbidity. There is growing evidence
that targeting ageing mechanisms can reduce or delay age-related diseases
in animal models, and the first reports of clinical trials are now appearing.
Although these trials currently focus on repurposed drugs, we propose
several novel targets that would more specifically target ageing processes
and thereby reduce multimorbidity and polypharmacy in future
generations.
Introduction
Over the past 200 years, advances in public health and medical interventions have led to a
dramatic increase in life expectancy, with current predictions suggesting that the total popula-
tion of people aged over 60 years will double to approximately 2.1 billion by 2050 [1]. However,
healthy life expectancy has not improved at the same pace, and so we are living longer but not
healthier. For example, a global increase in life expectancy of 5 years between 2000 and 2015 was
associated with only a 4.6-year improvement in healthspan [2]. In the UK, male life expectancy
increased by 4.2 years between 1990 and 2010, but healthy life expectancy lagged behind, with a
2.7-year increase (for females, the equivalent data were 1.9 years and 1.1 years) [3]. As a result, an
average of 16–20% of later life is spent in ill-health [4], with many individuals having age-related
chronic diseases, such as arthritis, cancer, type 2 diabetes mellitus (T2DM), and cardiovascular
and neurodegenerative disorders.
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IEWREVIEWS Drug Discovery Today Volume 25, Number 8 August 2020Crucially, older adults rarely experience just one of these con-
ditions, and multimorbidity has become the norm in old age [5].
Multimorbidity, which is defined as the coexistence of two or more
chronic conditions, is highly prevalent in high-income countries
and is on the rise in low- and middle-income countries [5]. Multi-
morbidity affects at least 50 million people in the European Union
[6], whereas 80% of Medicare users in the USA have at least two
chronic conditions [7]. Although not limited to older adults,
multimorbidity increases substantially with age, and is the main
risk factor resulting in shorter life expectancy, worsening func-
tional capacity, poorer quality of life, longer hospital stays, and
increased healthcare costs for ageing populations around the
world [8,9]. A cross-sectional study of 1.7 million people in Scot-
land found that 30.4% of people aged between 45 and 84 years,
64.9% of people aged between 65 and 84 years, and 81.5% of
people aged 85 years or above had at least two chronic diseases
[10]. Another notable statistic from this study is that multimor-
bidity onset can occur 10–15 years earlier in individuals living in
more socially deprived areas [10]. Furthermore, every additional
chronic disease in over 65 year olds shortens life expectancy by on
average 1.8 years [7]. There is now mounting evidence that treat-
ments effective in the single-disease context are far less so in the
context of multimorbidity, and that polypharmacy leaves patients
at serious risk of adverse effects [8,11]. The current challenge to
overcoming the issue of multimorbidity is that medical practice,
public health strategies, and drug discovery are still focused on
treating these diseases individually, even though this no longer
reflects the clinical reality for older patients and might even be
harmful because of polypharmacy [11]. Thus, there is an urgent
need for a novel approach to age-related multimorbidity, and we
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Disease clustering in multimorbidity. Cross-sectional studies recently identified pa
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rather than on its individual disease components. We suggest that
it is vital that we move away from the one drug/one disease model
for therapeutic interventions and drug discovery in multimorbid-
ity towards a more holistic approach that brings its underlying
causes into greater consideration. To achieve this, we need to
better understand how multimorbidity develops, the specifics of
different disease clusters in multimorbid patients, and the generic
mechanisms driving each cluster.
Disease clustering in multimorbidity
Cross-sectional studies have begun to characterise patterns of
associative multimorbidity, whereby specific pairings or clusters
of diseases develop in individuals at a higher rate than expected
from pure chance alone, in an attempt to provide useful evidence
for better clinical management of patients with multimorbidities
and to identify targetable pathways driving the different clusters
[12]. Such studies have been varied in their choice of sample size,
age setting, indices of multimorbidity, and statistical methodolo-
gy, leading to inconsistent results that are difficult to compare
between studies. Despite this variability, there does appear to be a
growing consensus from multiple studies across different popula-
tions, as reviewed by Prados-Torres et al. [12], that multimorbidity
patterns generally fall into three main clusters: cardiometabolic,
neuropsychiatric, and musculoskeletal (Fig. 1). A cardiometabolic
cluster, which was identified in ten of the 14 studies reviewed,
most commonly involved at least two diseases, such as diabetes,
hypertension, various types of heart disease (e.g., coronary heart
disease or congestive heart failure), hyperlipidaemia, and obesity.
A neuropsychiatric cluster was again identified in ten of the 14
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least one mental health condition. Of these, anxiety, depression,
and chronic pain were the most frequent and were associated with
a wide range of comorbidities, including, but not limited to, other
neurological diseases (e.g., dementia, delirium, and Parkinson’s
disease), respiratory problems [e.g., asthma or chronic obstructive
pulmonary disease (COPD)], gastrointestinal conditions [e.g., gas-
tro-oesophageal reflux disease (GORD) or liver disease], and mus-
culoskeletal disorders (e.g., osteoporosis or arthritis). The
musculoskeletal cluster included at least one musculoskeletal
disorder, with the most common being arthropathy, back/neck
pain, and osteoporosis. Similar to the neuropsychiatric cluster, a
variety of comorbidities, such as obesity, and cardiovascular and
neurological diseases, were commonly found within this cluster.
These insights into the complex interactions of multiple diseases
in multimorbidity are yet to be translated into clinical use for
patient benefit. However, alongside more longitudinal explora-
tions of multimorbidity trajectories to decipher when individuals
are at risk of developing their first and/or next disease [13],
clustering might hold the key to developing timely and targeted
drug therapies for patients displaying the early stages of a specific
multimorbidity cluster.
Targeting the potential generic drivers of
multimorbidity: core ageing processes
Given that advancing age is the primary non-modifiable risk factor
for developing many chronic diseases alone or concomitantly, a
new paradigm, the ‘geroscience hypothesis’, recently emerged for
preventing, delaying, or even reversing age-related diseases and
loss of function [14,15]. This concept is based on targeting the
largely interconnected cellular and molecular mechanisms that
underlie ageing, collectively termed the ‘Hallmarks of Ageing’ [16].
The strength of this hypothesis lies in the wealth of scientific
understanding of the biology of ageing and the remarkable prog-
ress that has been made recently in preclinical and human studies
to identify interventions that prevent and reduce the burden of
chronic disease with advancing age [17]. Undoubtedly, such an
approach also has the potential to revolutionise the way in which
we develop new drugs for multimorbidity by targeting the generic
drivers rather than focusing on single diseases within a cluster.
The ageing process underpins the progressive loss of function,
homeostasis, and resilience in multiple organ systems with time
and, once a particular threshold of impairment is reached, leads to
the development and accumulation of clinically discernible dis-
eases and/or frailty [18]. Although most older adults with frailty
also have multimorbidity, many people with multimorbidity are
not phenotypically frail; that is, those at high risk of adverse
outcomes, such as falls, disability, hospitalisation, and death,
because of a loss of physiological reserve [18]. Despite being
separate concepts, there is large overlap between frailty and multi-
morbidity, and frailty can usefully be considered as a tool to
identify older people with multimorbidity who are particularly
vulnerable to dramatic changes in their physical and mental
wellbeing. Established models of frailty, such as the ‘Phenotype’
model developed by Fried [19] and the Rockwood ‘Cumulative
Deficit’ model [20], often include aspects of function, such as
mobility impairment or difficulty with daily living activities,
which are commonly missing from multimorbidity models. Func-
tional improvements form a core component of many evidence-based interventions to improve outcomes in frail individuals, and
so measures of frailty can have an important role in geroscience-
guided clinical trials targeting multimorbidity. The exact timing of
multimorbidity onset is dependent on a multitude of genetic and
environmental factors including, but not limited to, gender, eth-
nicity, obesity, lower socioeconomic status, and education level
[8–10]. Delaying the progression to multimorbidity from the first
onset of disease is one possible approach to clinical trial design to
test the geroscience hypothesis that is being piloted in the Target-
ing Aging with Metformin (TAME) trial (discussed in more detail
later) [21]. Thus, the ageing hallmarks could represent novel
therapeutic targets in age-related diseases that commonly cluster
together in individuals with multimorbidity.
Hallmarks of ageing: potential targets for drug
interventions in multimorbidity
It is now widely recognised that nine interdependent cellular and
molecular mechanisms underpin the ageing process (the
‘Hallmarks of Ageing’) [16]. This biogerontological understanding
of ageing has determined that the initiating process is the accu-
mulation of damage to DNA and proteins, epigenetic alterations,
and reduced genome stability. This results in cellular responses
that produce the aged phenotype, including reduced nutrient
sensing, altered cell communication, reduced stem cell turnover,
mitochondrial dysfunction, reduced proteostasis, and, ultimately,
cell senescence [16].
The integrity and stability of the genome is continuously chal-
lenged by exogenous agents [e.g., ultraviolet (UV) radiation and
chemicals] as well as endogenous threats [e.g., replication-induced
DNA errors and telomere shortening, spontaneous hydrolytic
reactions, and reactive oxygen species (ROS)] [22]. Although
organisms have developed DNA repair mechanisms to minimise
these lesions [e.g., DNA damage responses (DDRs)] and maintain
the length and functionality of chromosomes (e.g., telomeres),
excessive DNA damage and insufficient DNA repair inevitably
result in genomic instability with chronological age [22]. Epige-
netic alterations, such as DNA methylation, histone modifications
(e.g., methylation and acetylation), and chromatin remodelling,
also take place constantly throughout the lifespan of an organism
to control gene transcription in response to environmental sti-
muli. Progressive deregulation of the ‘the writers, readers, and
erasers’ of epigenetic marks [e.g., DNA methyltransferases, histone
acetyltransferases, methyl CpG binding proteins (MBPs), and his-
tone demethylases] with age leads to epigenetic drift, which is
characterised by a loss of the normal balance of regulatory land-
marks within the epigenome [23,24]. The best example of this is in
DNA methylation, where ageing causes a bidirectional shift in
methylation patterns, resulting in global hypomethylation across
the genome [25], as well as hypermethylation at key regions of
genes (e.g., CpG islands) [26], which can eventually lead to chro-
matin compaction and gene silencing. Overall, these epigenetic
alterations contribute to the attenuated responsiveness to internal
and external signals, the loss of phenotypic plasticity, and reduced
regenerative capacity of stem cells, as well as the rise of hyperpro-
liferative somatic cells that promote cancer development [24].
These changes can also permit the reactivation of transposable
elements (TEs), such as the retrotransposon LINE1, which com-
monly compromise genomic integrity [27].www.drugdiscoverytoday.com 1405










IEWAnother mechanism that results in the accumulation of damage
and initiation of the ageing process is the loss of proteostasis. The
two main proteolytic systems involved in maintaining protein
quality control, namely the ubiquitin-proteasome and the autop-
hagy-lysosomal system, both become impaired with age [28]. Bulk
lysosomal degradation, known as autophagy, is responsible for
clearing long-lived proteins and damaged organelles, and is under
tight control from multiple transduction pathways based on en-
vironmental signals [29].
An important regulator of autophagy is the mammalian target
of rapamycin (mTOR) and, in its two multiprotein complexes
mTORC1 and mTORC2, it forms part of an interconnected net-
work of nutrient-sensing systems that affect a variety of cellular
processes [29]. Whereas mTOR senses high amino acid concentra-
tions and regulates almost all aspects of anabolic metabolism, the
insulin-IGF-1 signalling (IIS) pathway responds to changing levels
of glucose/insulin, as well as growth hormone (albeit indirectly via
IGF-1) [29]. Thus far, multiple lines of evidence from longevity
studies in animals [30] have suggested that strong anabolic and
trophic signals, via mTOR and IIS, are major contributors to
accelerated ageing, and the effects of dietary restriction (DR) on
increasing lifespan in model organisms are likely mediated via
modulation of these interconnected pathways. Other pertinent
nutrient-sensing systems implicated in the ageing process involve
AMPK and sirtuins, which detect changes in AMP and NAD
+ levels, respectively, to sense low energy states [29]. These nutri-
ent sensors act in opposition to mTOR and IIS to signal nutrient
scarcity and induce catabolic responses, and are accordingly upre-
gulated with age [29].
Mitochondrial function is also perturbed with age as a result of
mitochondrial DNA mutations, reduced mitochondriogenesis,
destabilisation of the ATP-generating electron transport chain,
and poorer quality control of damaged mitochondria by autop-
hagy (known as mitophagy) [31]. Whereas mild mitochondrial
dysfunction generates stress signals (e.g., ROS and low ATP pro-
duction) that induce survival signals and trigger compensatory
improvements in cellular fitness, in a process termed mitohorm-
esis [32], with time these changes surpass a threshold that means
oxidative stress becomes pathogenic [33].
Cellular senescence is a state of irreversible cell-cycle arrest,
which can be induced by telomere shortening, DDRs, and mito-
chondrial stress [34]. Although senescent cells do not divide, they
are metabolically active and secrete a variety of extracellular
mediators, such as matrix metalloproteinases (MMPs), growth
factors (vascular endothelial growth factor; VEGF), proinflamma-
tory cytokines [e.g., interleukin-1 alpha (IL-1a) and IL-6), and
chemokines (IL-8), collectively referred to as the senescence-asso-
ciated secretory phenotype (SASP) [35]. The SASP has an important
physiological role by recruiting immune cells to clear apoptotic
cell debris for wound healing (e.g., by macrophages) and senescent
cells themselves (e.g., by natural killer cells) [36]. However, with
ageing, there is an accumulation of senescent cells, in part because
of reduced immune-mediated elimination [37], thus causing ab-
errant tissue function and repair [34].
The SASP also contributes to the chronic, low-grade inflamma-
tion, termed ‘inflammageing’, which is a primary example of
altered cell communication as a hallmark of ageing [38]. Inflam-
mageing is characterised by reduced levels of anti-inflammatory1406 www.drugdiscoverytoday.comcytokines, such as IL-10, and increased proinflammatory cyto-
kines, such as IL-6 and IL-8, in the blood of older individuals
[38]. Other potential contributors to inflammageing include im-
pairment of the immune system with age (immunosenescence),
increased adiposity, reduced physical activity, and leakage of
microbial components from mucosal cavities into the blood be-
cause of reduced mucosal barrier integrity [39]. Importantly, the
degree of inflammageing is associated with an increased risk of a
range of chronic conditions, including cardiovascular disease,
sarcopenia, osteoporosis, and dementia [40], and, thus, is a key
potential driver of multimorbidity.
These highly interconnected core ageing processes not only
provide a potential route to understanding the complex process
of ageing and age-related diseases, but also offer an exciting
opportunity to treat the generic drivers of multimorbidity to
extend human healthspan.
Experimental evidence for targeting hallmarks of
ageing in age-related disease and multimorbidity
Cellular senescence
Reducing the burden of senescent cells within tissues is one
potential method of exploiting an ageing hallmark in the context
of individual age-related diseases or multimorbidity, and has
recently shown promise as a geroscience-informed therapeutic
approach in a range of age-related diseases. Seminal papers in
2011 and 2016 showed that transgenic mice that selectively delet-
ed senescent cells as they arose during midlife and old age had
delayed tumorigenesis and age-related deterioration of several
organs, including the heart, kidneys, eyes, skeletal muscle, and
fat tissue [41,42]. Several existing drugs are able to induce apopto-
sis in senescent cells, so-called ‘senolytics’, including dasatinib
(ephrin receptor inhibitor), quercetin (PI3 kinase pathway inhibi-
tor), and navitoclax (Bcl-2/Bcl-xL anti-apoptotic protein inhibitor)
[43–45]. Such compounds have now been tested in several pre-
clinical disease models, showing improvements in cardiac [46] and
vascular function [47], atherosclerosis [48], osteoporosis [46], os-
teoarthritis [49], and cognitive decline in tau-dependent neuro-
degenerative disease [50], while also attenuating frailty and
prolonging overall healthspan and lifespan [51]. Encouragingly,
the first human trials of senolytics, a combination of dasatinib and
quercetin, have reported promising early results, which are dis-
cussed in more detail later [52,53]. Screening of compound librar-
ies has also led to the discovery of novel senolytics, including
selective Bcl-xL inhibitors [54], fisetin [54,55], heat-shock protein
90 (HSP90) inhibitors [56], and cardiac glycosides [57,58].
In an alternative approach, senostatic drugs, which target the
secretory activity of senescent cells and in doing so reduce inflam-
mageing, have also been tested. Selective inhibition of the JAK1/2
pathway was shown to have senostatic activity, reducing systemic
inflammation, improving metabolic function and fat tissue ho-
meostasis, and enhancing physical capacity in old, frail mice [59].
Small-molecule p38 inhibitors have also been effective in reversing
T cell senescence and boosting vaccine efficacy in mice [60], and
reducing inflammation and boosting cutaneous immunity to viral
challenge in older humans [61].
Despite the evidence from animal models that the removal of
senescent cells can have a positive impact upon ageing in several

































Geroscience-guided clinical trials of drugs targeting hallmarks of ageinga,b
Drug Target hallmark Patient cohort Duration Dose Outcome measures NCT no.
Metformin Nutrient sensing N = 16; 60 years +;
glucose intolerant
6 weeks 1700 mg daily versus placebo Transcriptome changes in muscle and
adipose tissue; insulin sensitivity and
secretion
NCT02432287
N = 109; 65 years +;
SPPB score 3–12
16 weeks 1700 mg daily + RET versus
placebo + RET
Type II myofibre CSA; normal density
muscle size; muscle strength and total lean
body mass insulin sensitivity
NCT02308228
Autophagy N = 25; 30–70 years;
prediabetic; BMI 27–
40
12 weeks 500 mg twice daily titrated to
1500 mg over 1 month versus
placebo
LC3 as marker of autophagy NCT03309007
Nutrient sensing N = 120; 65 years +;
prediabetic
Up to 3 years 850 mg once daily titrated to
850 mg twice daily versus placebo
Total lean body mass; 400 m walk speed




N = 12; 60 years +;
prediabetic; stable
CAD; frail (SPPB score
<9)
1 year Up to 2 mg, given as 500 mg every
6–8 hr versus placebo
Frailty based on SPPB score; balance, gait
speed, standing from chair; serum IL-6,
MMPs, MCP-1, activin and plasminogen
activator inhibitor as senescent markers
NCT03451006
Immunosenescence N = 50; 63–89
years







Nutrient sensing N = 120; 60-90 years;
prediabetic
2 years Up to 1000 mg twice daily versus
placebo
Fried composite frailty score NCT02570672
N = 150; 60 years +;
prefrail
16–24 weeks 500 mg thrice daily versus placebo Frailty index (40 items); health-related
quality-of-life questionnaire; gait speed,







N = 148; 40–75 years;
healthy
12 weeks 1500 mg daily versus placebo Insulin sensitivity; mitochondrial function
(complex I activity in ETC); blood glucose,
insulin, and HbA1c levels
NCT04264897
Nutrient sensing N = 30; 60 years
+; healthy
19 days 1 g twice
daily for 2
weeks before
5 days of bed
rest versus
placebo







N = 10; 55 years+;
female only; healthy
4 weeks Combined topical formulation of all
three drugs versus metformin and
diclofenac combination
Gene transcript changes; Wrinkle score NCT03072485
Rapamycin Nutrient sensing N = 144; 18–85 years;
healthy
8 hours Single 16 mg dose (Rap) + AA
supplement, HIRET + Rap, HIRET
+ AA, or Rap + AA + HIRET
Muscle protein synthesis; phosphorylation



















































TABLE 1 (Continued )
Drug Target hallmark Patient cohort Duration Dose Outcome measures NCT no.
Dasatinib
+ quercetin
Senescence N = 16; 40–80 years;
DKD
2 weeks 100 mg dasatinib +1000 mg
quercetin daily for 3 consecutive
days; versus no intervention group
Senescent cell burden in skin, fat and
blood; mesenchymal stem cell function;
frailty index; kidney function
NCT02848131
N = 5; 65 years +;
early AD
12 weeks 2 days on/2 weeks off dasatinib
+ quercetin (six cycles)
Brain penetrance of dasatinib/quercetin;
Tau and amyloid-beta protein levels in CSF;
IL-6 and p16 levels in CSF; gait speed;
Montreal Cognitive Assessment
NCT04063124
N = 26; 50 years +;
IPF; Male
3 weeks 100 mg dasatinib and 1250 mg
quercetin daily 3 days/week over 3
weeks versus placebo
Inflammatory and senescent cell markers in
skin and plasma (e.g., IL-6 and p16)
NCT02874989
Quercetin Senescence N = 106; healthy; 18–
75 years
6 months 500 mg daily versus placebo HIF-1, VEGF, EPO, and eNOS levels in blood;






Senescence N = 56; healthy; 40–
60 years
6 months 650 mg quercetin + curcumin, fish
oil, resveratrol, sesamin, acetyl-L-
carnitine, lipoic acid, green and
black teas, pomegranate extract
and cinnamon bark versus
multivitamin/mineral control group
Arterial stiffness by carotid-femoral pulse






N = 40; 70 years +;
female only
2 months 20 mg/kg daily for 2 consecutive
days for 2 months versus placebo
Gait speed NCT03430037
N = 40; 70 years + N/A 20 mg/kg daily for 2 consecutive
days only versus placebo
Blood inflammatory markers NCT03675724
N = 30; 40-80 years;
CKD or DKD
12 months 20 mg/kg daily for 2 consecutive
days only versus placebo
Inflammatory markers (e.g., CRP);
mesenchymal stem cell function (e.g.,
migration); Fried composite frailty score;
kidney function
NCT03325322
N = 72; 40-80 years;
OA
18 months 20 mg/kg daily for 2 consecutive
days, followed by 28 days off, then 2
more consecutive days versus
placebo
Systemic inflammatory markers; cartilage
degeneration markers; MRI of knee
articular cartilage; physical function (e.g.,
timed up and go, chair test); patient-
reported outcomes of knee function and
pain; time to start of alternative treatment
NCT04210986





N = 30; 30–79 years;
CKD
6 weeks 500 mg coenzyme Q10 twice daily,
or; 600 mg NR twice daily versus
placebo
Maximal aerobic capacity; PBMC
mitochondrial energetics; oxidative stress
and inflammatory markers; metabolomics;








N = 55; 60–79 years;
healthy
6 weeks 20 mg daily MitoQ versus placebo Oxidative stress (systemic oxidized LDL
levels and nitrotyrosine in endothelial
cells); cognitive function; arterial stiffness;
motor function
NCT02597023
aGiven the wealth of preclinical evidence from animal models that ageing hallmarks can be targeted to delay and/or improve age-related diseases and frailty, human clinical trials are underway to investigate drugs known to target these core
ageing processes. The use of diverse outcome measures that include biomarkers of ageing as well as more disease-specific measures will be vital to provide best possible evidence of efficacy for drug interventions.
b Abbreviations: AA, amino acid; AAV-hTERT, adenovirus-associated human telomerase reverse transcriptase; AD, Alzheimer’s disease; BMI, body mass index; CAD, coronary artery disease; CFS, clinical frailty score; CKD, chronic kidney disease;
CRP, C-reactive protein; CSA, cross-sectional area; CSF, cerebrospinal fluid; DKD, diabetic kidney disease; eNOS, endothelial nitric oxide synthase; EPO, erythropoietin; ETC, electron transport chain; HbAc1, glycated haemoglobin; HIF-1, hypoxia
inducible factor; HIRET, high-intensity resistance exercise training; IL-6, interleukin-6; IPF, Idiopathic pulmonary fibrosis; LC3, microtubule-associated protein 1A/1B-light chain 3; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant
protein-1; MMPs, matrix metalloproteinases; MRI, magnetic resonance imaging; NR, nicotinamide riboside; OA, osteoarthritis; PBMC, peripheral blood mononuclear cells; PCV13, pneumococcal conjugate vaccine; RET, resistance exercise

































stringently in humans to validate these preclinical findings and
minimise potential translational risks. Accordingly, there are sev-
eral clinical trials underway using senolytics in age-related disease/
frailty cohorts (Table 1) to evaluate the safety, feasibility, and
efficacy of such interventions.
Mitochondrial dysfunction
Targeting the ageing hallmark of mitochondrial dysfunction has
shown potential in several age-related pathologies. NAD levels
decline with age and, although direct supplementation of NAD
itself has had little success, NAD precursors, such as nicotinamide
mononucleotide (NMN) and nicotinamide riboside (NR), have
been more successful in increasing NAD tissue bioavailability
[62]. For example, long-term NMN administration mitigates phys-
iological decline in mice during normal ageing, with improve-
ments in insulin sensitivity, plasma lipid profile, and eye and bone
function, while simultaneously enhancing mitochondrial oxida-
tive metabolism and attenuating age-associated mitonuclear pro-
tein imbalance in skeletal muscle [63]. In the context of obesity,
NR supplementation protects against high-fat diet-induced meta-
bolic abnormalities and defective mitochondrial function via the
activation of SIRT1 and SIRT3 [64].
To date, the efficacy of NAD restoration in humans is less clear.
Short-term NR supplementation has been shown to be well toler-
ated in middle-aged and older adults, leading to effective stimula-
tion of NAD metabolism, as well as improvements in
cardiovascular health [65] and decreased levels of circulating
proinflammatory cytokines [66]. However, another clinical trial
reported that NR supplementation in middle-aged, obese men
with insulin resistance had no effect on NAD levels, respiratory
capacity of skeletal muscle mitochondria, mitochondrial protein
abundance, and mitochondrial fractional area [67]. Clinical trials
using NR or Coenzyme Q10 derivatives are ongoing and will be
vital in understanding the best possible way to target mitochon-
drial dysfunction and how this might impact other interconnected
ageing hallmarks (Table 1).
Mitophagy and autophagy inducers
Urolithin A (UA), which is a natural dietary microflora-derived
metabolite, specifically activates mitophagy and improved muscle
health in animal models of ageing [68]. In a recent first-in-human
clinical trial, synthetic UA supplementation had a good safety
profile in old individuals and induced skeletal muscle gene expres-
sion changes indicative of improved mitochondrial function [69].
Spermidine, another inducer of mitophagy and autophagic flux in
general, has also been tested as a dietary supplement in several
preclinical animal models. So far, it has been shown to reduce
hyperlipidaemia-induced atherosclerosis [70], protect against
physiological cardiac ageing and heart failure [71], and reverse
B cell senescence [72]. Spermidine-based nutritional interventions
have now entered into a Phase IIb human clinical trial (SmartAge
trial: NCT03094546) to investigate their effect on memory perfor-
mance in older individuals with subjective cognitive decline and
potential neurophysiological mechanisms of action [73].
Nutrient-sensing modulators
In addition to autophagy, other upstream components of the
nutrient-sensing pathways can be manipulated to affect the ageingprocess. Although originally approved for its immunosuppressive
effects in acute renal allograft rejection, rapamycin (sirolimus),
which inhibits the mTOR complex that is central to nutrient and
growth factor-sensing pathways, is arguably the most well-estab-
lished therapeutic approach based on geroscience to date [74].
Although only mTORC1 is directly inhibited by rapamycin, chron-
ic exposure inhibits mTORC2 assembly and is thought to be
responsible for the adverse effects associated with long-term rapa-
mycin use [75].
Although rapamycin is still being tested in clinical trials (Table
1), more specific mTORC1 inhibitors will be key in overcoming
this problem and novel rapamycin analogues (also termed
‘rapalogs’) have already been shown to have high selectivity
[76]. Thus far, acute treatment with rapamycin (or rapamycin
analogues) to inhibit mTORC1 in animal models has been effec-
tive in delaying, or even reversing, almost every age-related disease
or decline in function, including cancer, cardiovascular disease,
kidney disease, obesity, neurodegenerative diseases, sarcopenia,
and immune senescence [77]. To date, only four human studies
have investigated mTORC1 inhibition in the context of ageing,
mainly immune system decline. The first study reported that
weekly treatment with the rapamycin analogue RAD001 (ever-
olimus) for 6 weeks in healthy old individuals was shown to be
relatively well tolerated and improved the immune response to
influenza vaccination [78]. Similarly, 6-week low-dose combina-
tion treatment with RAD001 alongside the catalytic site mTOR
inhibitor BEZ235 was safe and led to decreased infection rates over
a 12-month period in old subjects owing, at least in part, to an
improved response to influenza vaccination [79]. Although 8-week
treatment with rapamycin at a higher dose of 1 mg per day was
shown to be safe in healthy older individuals, no beneficial effects
on cognitive and physical performance, or clinical laboratory and
self-perceived health status, were observed [80]. Most recently,
topical low-dose application of rapamycin to the skin in a group of
over 40-year olds was shown to increase collagen VII levels and
reduce senescent cell-associated p16-INK4A expression within the
skin [81].
Metformin, which is approved for treatment of T2DM, targets
several ageing hallmarks because it leads to decreased insulin
levels, decreased IGF-1 signalling, inhibition of mTOR, inhibition
of mitochondrial complex I in the electron transport chain, re-
duced endogenous ROS production, and activation of AMPK [82].
Metformin also favourably affects metabolic and cellular processes
that contribute to inflammation, autophagy, and cellular senes-
cence, although it is unclear whether it affects all these pathways
directly, or whether the observed effects are downstream of its
single action on one mechanism of ageing [82]. Beyond these
cellular processes, there is growing evidence from preclinical
studies that metformin can delay ageing and prolong lifespan
and healthspan. In mice, for example, metformin increased life-
span by 4–6% and improved multiple healthspan indices, such as
physical performance and insulin sensitivity. As expected, these
improvements were accompanied by increased AMPK activity,
decreased chronic inflammation, and reduced oxidative damage
[83]. However, these preclinical findings must be interpreted with
some caution for several reasons. First, although mice are geneti-
cally tractable and allow testing of how candidate drugs impact
evolutionarily conserved mechanisms of ageing, they are by nowww.drugdiscoverytoday.com 1409










IEWmeans ideal as models of human ageing given the significant
difference in lifespan compared with humans. Second, the life-
span-extending effects of metformin have not been replicated by
the National Institute on Aging Interventions Testing Program,
which tests the effects of drugs on longevity in three different
locations using genetically heterogeneous mice. This might reflect
the original effect being seen in only in male inbred mice, which
are susceptible to obesity [84]. Third, high-dose metformin (1% w/
w in diet) shortened the average lifespan in mice [83] and, thus, it
will be important to identify safe dosing regimens in humans
when determining the translational potential of metformin.
In humans, metformin has been shown to be effective in pre-
venting T2DM in at-risk (obese or glucose-impaired) middle- and
old-aged adults, while concomitantly improving cardiovascular
disease risk factors and subclinical atherosclerosis [85]. In a pilot
study in over 60-year olds with impaired glucose tolerance, 6 weeks
of metformin use significantly altered metabolic and non-meta-
bolic genes in both muscle and adipose tissue. Interestingly, these
tissue-specific changes were predicted to be a result of metformin
influencing upstream transcriptional regulators, such as mTORC1,
as well as key ageing pathways linked to DNA repair, mitochon-
drial fatty acid oxidation, and inflammation [86]. Furthermore,
metformin use has been associated with decreased cancer inci-
dence, reduced cognitive impairment, lower rates of neurodegen-
erative diseases in older patients with T2DM, and reduced overall
mortality in patients with T2DM as well as nondiabetics [82]. In
contrast to these positive indications, metformin exposure in older
patients with T2DM was associated with an increased risk of
Alzheimer’s disease, vascular dementia, and Parkinson’s disease,
and these observations were linked to increased dosage and dura-
tion of use [87]. A link between metformin use, increased risk of
vitamin B12 and vitamin B6 deficiency, and cognitive dysfunction
in older adults has also been reported [88]. Findings from recent
clinical trials examining the effects of metformin alongside aero-
bic and/or resistance exercise training (AET/RET) in older adults
were again contrary to expectation [89,90]. Metformin attenuated
the improvement in insulin sensitivity and cardiorespiratory fit-
ness after AET by inhibiting mitochondrial respiration in skeletal
muscle [89], while preliminary results from the MASTERS trial
(NCT02308228) found that long-term metformin use blunted the
hypertrophic response to exercise and could not boost numbers of
muscle-resident M2 (anti-inflammatory) macrophages after RET
[90].
Such conflicting findings regarding metformin use in humans
warrant future large-scale clinical trials. Currently, there are 11
clinical trials in the USA using metformin in patients with age-
related conditions or frailty, aiming to reduce disease indicators or
improve physical function respectively (Table 1). These trials will
also be vital in discerning whether metformin can impact the root
causes of ageing, beyond its known beneficial effects on metabo-
lism. Monitoring effects on several hallmarks of ageing in these
trials will have an important role in addressing this question.
Biomarkers of ageing for geroscience-guided clinical
trials of multimorbidity
Any progress in preventing multimorbidity and late-life poor
health will inevitably come from better predictors of their occur-
rence and the ability to intervene and monitor therapeutic1410 www.drugdiscoverytoday.comresponses in individuals at greatest risk of developing multimor-
bidity. The use of surrogate biological measures, biomarkers, to
detect individual variability in the progress of ageing as a risk
indicator (i.e., accelerated ageing) and to monitor responses to
interventions will be vital in testing the geroscience hypothesis.
According to the American Federation for Aging Research (AFAR),
these biomarkers should ideally: (i) predict the rate of ageing (i.e.,
mark exactly where an individual is in their lifespan) and mortality
independent of chronological age; (ii) monitor a fundamental
ageing process and not the effects of disease; and (iii) allow for
practical (i.e., via blood test or imaging) longitudinal tracking in
laboratory animals and humans [91]. Although there is no broad
consensus on biomarkers of ageing for use in clinical trials, an
expert panel convened in 2017 proposed a list for use in ger-
oscience-informed trials, which included markers for: inflamma-
tion [C-reactive protein (CRP) and IL-6); mitochondrial stress
(GDF15); nutrient signalling (IGF-1 and fasting insulin); kidney
function (cytostatin C); cardiovascular health (NT-proBNP); and
metabolic ageing (glycated HbA1c) [21].
Several biomarkers of physiological state, including standar-
dised measures of physical and mental capacity (e.g., cardiovascu-
lar and lung function, locomotion, strength, balance, and
cognition) and systemic regulation of metabolism and immunity
(e.g., insulin, IL-6, and CRP) have also been proposed for use in
such trials [91]. Composite indices, such as the ‘Biological Age’ and
‘Pace of Aging’ scores, comprising many of these single biomark-
ers, can identify early-/middle-aged individuals at higher risk of
impending multimorbidity because of accelerated ageing [92].
Other algorithmic measures of physiological vulnerability include
the well-characterised ‘frailty phenotype’ [19], which is commonly
used in the clinic, as well as the more recently developed frailty
index (FI)-LAB [93], which uses commonly employed laboratory
tests to generate a composite index of frailty. Such outcome
measures might be more appropriate to monitor the effectiveness
of interventions in older patients with established multimorbidity.
Recently, other indicators of biological age based on the epi-
genome [94], metabolome [95], and transcriptome [96] have been
developed. For example, the ‘Horvath epigenetic clock’ is a multi-
tissue DNA methylation-based predictor of chronological age
based on the cumulative effect of the epigenetic maintenance
system [94]. Deviation from the predicted chronological age of
a subject using this tool is suggested as an indicator of their true
biological age. This tool might have particular use in multimor-
bidity because it can elucidate tissue-specific accelerated ageing
resulting from different diseases, and might enable us to identify
which multimorbidity clusters should be targeted therapeutically.
To date, these tools have not been extensively tested in clinical
trials of drugs targeting ageing processes, but encouragingly they
are starting to be adopted in some more recent geroscience-guided
clinical trials, which are discussed in more detail in the following
section.
Exemplars of geroscience-guided clinical trials
The exclusion of patients with multimorbidity from clinical trials is
common, and often based on the proposition that the presence of
comorbidities might dilute any potential benefits for the primary
condition, or exacerbate any adverse effects of the treatment under
investigation. The assessment of ongoing randomised controlled














trials (RCTs) for patients with ten common chronic conditions
registered between 2014 and 2015 in the UK found that 79% of
these RCTs excluded patients with a chronic comorbidity, while
only 12% of RCTs were investigating interventions specifically for
patients with more than two chronic conditions [97]. A study of
more recent industry-sponsored clinical trials of novel drug thera-
pies for chronic conditions found that the mean comorbidity count
for trial participants in the UK was approximately half that seen in
community-based patients, with no comorbiditiesbeing foundto be
particularly well represented across any of the trials [98]. It is vital
that any large-scale geroscience-guided clinical trials are designed to
include individuals across the multimorbidity spectrum, including
at-risk individuals, patients with a single disease, and patients with
established multimorbidity, to determine how interventions can
stop or slow progression from single disease to multimorbidity.
Outcome measures should also reflect this transition by measuring
time to next disease diagnosis or new disease incidence in a particu-
lar timeframe, and although expensive, will require multiple follow-
ups totrack longitudinal changesover monthsand potentiallyyears.
Despite the paucity of clinical trials that specifically target multi-
morbid patients, here we highlight exemplars of geroscience-guided
clinical trials that have begun to pave the way for improved drug
discovery in the prevention and treatment of multimorbidity.
The first of these is the Thymus Regeneration, Immunorestora-
tion, and Insulin Mitigation (TRIIM) trial, which was designed to
investigate whether a combination therapy of recombinant
growth hormone (rGH), dehydroepiandrosterone (DHEA), and
metformin could prevent or reverse immunosenescence as an
aspect of human ageing in healthy 51- to 65-year-old men [99].
The choice of drug formulation was based on prior evidence that
growth hormone has thymotrophic and immune-reconstituting
effects in animals [100] and patients with HIV [101], and that
DHEA and metformin would be important to limit the diabeto-
genic properties of rGH administration. In addition, both DHEA
[102] and metformin [82,84] have been shown to target aspects of
the ageing process. This multidrug intervention for 12 months did
restore thymic functional mass, and led to systemic increases in
the lymphocyte:monocyte ratio, naı̈ve CD4 and CD8 T cell pool,
and frequency of CD4 recent thymic emigrants, all of which
provide evidence of immunosenescence reversal [99]. Further to
this and arguably more interesting, participants exhibited a sig-
nificant decrease in their biological age based on four epigenetic
clock biomarkers [99]. Overall, there was an average reduction in
biological age of 2.5 years after 12 months and 1.5 years even after
3 months of treatment cessation [99]. Furthermore, the rate of
ageing regression was shown to accelerate in months 9–12 after
trial onset using all four epigenetic clock biomarkers, suggesting
that even more long-term benefits are achievable with continua-
tion of this combination drug therapy [99]. The TRIIM trial is a
primary example of a geroscience-guided clinical trial that aims to
prevent primary disease development in middle-to-old aged indi-
viduals at risk of developing their first age-related disease. Al-
though the primary outcome of this study was to target
immunosenescence, it made use of epigenetic age as another
biomarker of ageing to provide evidence that multidrug formula-
tions warrant further investigation in large-scale clinical trials,
given their ability to impact the ageing process and mitigate each
other’s potential adverse effects.Although preventative management of multimorbidity might
be the ideal end goal, there is also a need to prevent progression
from single diseases to established multimorbidity, which greatly
complicates a patient’s clinical management. The TAME trial aims
to obtain evidence for a new indication in the use of metformin as
a drug to delay multiple age-related diseases, as well as provide a
geroscience-guided platform for trial design to test next-genera-
tion drugs [21,103]. Uniquely, the TAME trial plans to test met-
formin in older subjects with impending multimorbidity because
of an ongoing single chronic disease, such as obesity, metabolic
syndrome, hypertension, or hyperlipidaemia, and, rather than
study the impact on each condition in isolation, its primary
outcome will be to measure the time to new diagnosis of a second
specific age-related disease, including cardiovascular events, can-
cer, dementia, and death [21,103]. Secondary and tertiary out-
comes of the trial will include the accumulation rate of other age-
related chronic conditions, such as depression, osteoporosis, and
osteoarthritis, and acute events, such as falls and pneumonia, as
well as functional (e.g., gait speed) and quality-of-life measures (e.
g., pain or sleep quality). This focus on the accumulation of age-
related diseases and functional endpoints associated with frailty
marks a paradigm shift in clinical trial design, moving away from
the one drug/one disease model towards targeting ageing processes
and monitoring multiple disease outcomes instead. In such trials
focusing on endpoints, such as disease diagnosis or death, bio-
markers will be vital to help show that the intervention in question
is affecting the underlying biology of ageing before sufficient
clinical evidence is apparent, which could take many years. As a
result, as described earlier, an expert workgroup has identified a list
of candidate blood-based biomarkers that could be applied in
geroscience-guided clinical trials, such as TAME [21]. Such trial
designs will be key to stimulating new pharmacological therapies
to tackle the challenge of multimorbidity.
Finally, in individuals with well-established multimorbidity,
newly discovered drugs would ideally be able to reverse chronic
diseases and, if not, should at least be able to slow their progression
so as to maintain or improve function and late-life quality of life.
First-in-human clinical trials using the senolytic drugs dasatinib
and quercetin (DQ) have now begun to test this possibility, with
some promising preliminary results. One pilot study showed that
short-term intermittent administration (three doses per week for 3
weeks) of DQ in patients with idiopathic pulmonary fibrosis (IPF),
which is a cellular senescence-driven disease, was feasible and safe,
and, more importantly, improved measures of physical function
(e.g., 6-min walk distance, 4 m-gait speed, and chair-stand time)
[52]. Although these measures of physical function were signifi-
cantly and clinically meaningfully improved, other outcomes,
including pulmonary function, circulating SASP factors, and FI-
LAB, were not significantly different and only showed a trend
towards improvement that might be attributable to the very small
sample size in this pilot study [52]. Despite this, moderate correla-
tions were seen between physical function improvement and these
other biomarkers. For example, faster 4 m-gait speeds and chair-
stand times were associated with decreased levels of different SASP
factors, and improved FI-LAB with many proinflammatory cyto-
kines [52]. Another pilot study in patients with diabetic kidney
disease showed that just a 3-day DQ treatment reduced senescent
cell burden in the skin and adipose tissue [53]. Accordingly,www.drugdiscoverytoday.com 1411
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and adipose tissue-resident macrophages were also reduced after
DQ treatment [53]. Although much remains to be done to optimise
systemic administration of senolytic drugs, they might hold huge
potential in the treatment of multimorbidity, given the wide-
ranging benefits of the systemic removal of senescent cells in
many age-related diseases.
Novel ageing targets and future directions
The field of geroscience is moving fast with regards to repurposed
drugs that were not originally designed to target a specific aspect of
the ageing process per se (e.g., metformin, rapamycin, dasatinib,
quercetin, and navitoclax). Therefore, developing drugs that spe-
cifically target core ageing processes has the potential to improve
efficacy and reduce adverse effects for patients with multimorbid-
ity, already at high risk of adverse effects because of polypharmacy.
Examining the efficacy of different rapalogs [104], such as RAD001
and BEZ235, which have already been effective against immuno-
senescence in human trials [78,79], in the context of other age-
related diseases is an important consideration because the impact
upon mTORC signalling can vary greatly based on the different
biochemical properties of the rapalogs. The discovery of natural
mimetics of metformin and rapamycin with better safety profiles,
by applying bioinformatics and deep learning methods to natural
compound libraries, has already yielded some promising novel
candidates [105].
Screening of chemical or natural compound libraries will facili-
tate the discovery of drugs that target some of the more novel
molecules regulating the ageing hallmarks (Table 2). For example,
transposable elements (TEs), which can move within the genome,
build up, and contribute to genomic instability in the ageing
process, are one such novel target [106]. The Piwi-piRNA pathway,
which was originally discovered in the Drosophila male germline to
repress the activity of TEs [107], is also active within human
haematopoietic stems cells [108], and might represent a targetableTABLE 2
Potential novel drug targets based on ageing hallmarks for age-re
Novel target Ageing Hallmark 
Transposable elements/Piwi-piRNA
pathway
Genomic instability; stem cell exhau
MANF Nutrient sensing; altered cell commu
NLRP3 inflammasome Altered cell communication /inflamm
NLRC4 inflammasome Altered cell communication /inflamm
Kalirin (KLRN) Altered cell communication 
KLHL20 Autophagy; nutrient sensing 
V-ATPases Autophagy 
Rheb Nutrient sensing; autophagy 
SIRT1, SIRT3, SIRT6 Genomic instability; nutrient sensing
Parkin/PINK1 Autophagy; mitochondrial dysfuncti
Alpha-klotho Mitochondrial dysfunction; altered c
Cdc42 Senescence; stem cell exhaustion 
cGAS/STING Genomic instability; senescence; alte
ROCK Mitochondrial dysfunction; senescen
(i.e., Inflammageing)
Retrotransposable elements (e.g., LINE1) Genomic instability; senescence; alte
Sestrins Senescence; nutrient sensing; autop
LRRK2 Mitochondrial dysfunction; autophag
PARP1 Genomic instability; mitochondrial d
a Listed are recently discovered molecules or pathways that have been implicated in the agei
delay, prevent, or reverse components of multimorbidity.
1412 www.drugdiscoverytoday.compathway to oppose TE-mediated genomic instability and stem cell
exhaustion. Mesencephalic-astrocyte-derived neurotrophic factor
(MANF) is a stress-response protein now shown to have immuno-
modulatory and systemic anti-inflammatory properties capable of
improving age-related metabolic dysfunction and liver disease
[109], and has potential for therapeutic application. Selective
small-molecule inhibitors of the NLRP3 inflammasome to target
inflammageing have also shown promise in preclinical studies
[110,111]. Trial design when testing any candidate drugs against
these ageing targets needs serious consideration. The inclusion of
patients with multimorbidities in clinical trials will be important
to test whether the benefit:risk ratio of any pharmacological
intervention is sufficient in the context of expected disease pro-
gression and pre-existing adverse effects from polypharmacy. For
some trial designs, this decision might be similar to that for
chemotherapy in advanced cancers, whereas trials testing drugs
for primary prevention might have to be more cautious. Different
approaches, whereby one drug or drug type is tested using several
primary outcomes in a ‘basket trial’ design, or several drugs target-
ing different ageing hallmarks are investigated in an ‘umbrella
trial’ design, such as the TRIIM trial, will maximise the probability
of clarifying which pharmacological approach works best for
different multimorbidity clusters. Taking advantage of some of
these novel drug targets (Table 2) might enable us to maximise the
therapeutic impact by targeting multiple ageing hallmarks simul-
taneously, in the hope that an additive, synergistic effect would be
of greater benefit to patients falling within a particular multi-
morbidity cluster. Targeting NLRC4, an important contributor
to inflammageing [112,113], kalirin (KALRN), a multifunctional
signalling protein implicated in atherosclerosis and neurodegen-
eration [114–117], and KLHL20, a master regulator of autophagy
termination [118] would be just one example of doing this to
indirectly impact many of the interconnected ageing hallmarks at
once (Fig. 2). Thus far, combination therapies of more well-known
candidate drugs have shown promising early results in their abilitylated diseases and multimorbiditya
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FIGURE 2
Targeting multiple ageing hallmarks simultaneously using novel drug targets. Novel drug targets, such as kalirin (KALRN), KLHL20, and NLRC4, which fall at the
nexus between multiple ageing hallmarks (e.g., altered cell metabolism/communication, inflammation, senescence, and DNA damage/repair) might be one
method of maximising therapeutic impact for patients with multimorbidity in geroscience-guided clinical trials. Arrows represent how core ageing processes [e.
g., oxidative stress, immune factors, senescence-associated secretory phenotype (SASP), DNA damage response (DDR), and telomere/replication stress] link














to target core ageing processes in animal models [119,120] and
humans [52,53,79,99].
Nonetheless, such multidimensional geroscience-guided clinical
trials for multimorbidity will need substantial funding, given the
necessity for long-term follow-ups to truly test the antiageing po-
tential of candidate drugs. Although industry-based funding will
have an important role in this, pharmaceutical companies might be
less inclined to fund such geroscience-guided clinical trials because
of their inherent risks and the fact that ageing is still not considered
an indication for drug development by the US Food and Drug
Administration (FDA) [21]; thus, government funding will be a
necessity. The establishment of national networks, such as the
National Institute on Ageing (NIA) R24 Geroscience Network, which
comprises 18 ageing centres and academic groups across the USA,
will facilitate accelerated progress infunding,drugdevelopmentand
human testing via the shared generation of standardised ‘toolkits’for ageing-related outcomes and adverse events that are comparable
across multiple trials, as well as a national geroscience biobank to
facilitate widespread, invaluable access to biological samples gener-
ated from unique cohorts of frail and older individuals with multi-
morbidities enrolled in clinical trials [14].
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